[Antiaggregant activity of hypoglycemic drugs].
We have compared the inhibitory effects of a series of hypoglycemic drugs, including glyclazide, glibenclamide, glucophage, rosiglitazone, diabenol (a new antidiabetic drug), and acetylsalicylic acid (reference antiaggregant preparation), on rabbit platelet aggregation in vitro induced by adding 5 mM ADP solution. All hypoglycemic drugs and acetylsalicylic acid inhibited platelet aggregation in a dose-depended manner. Diabenol, glyclazide and glibenclamide demonstrated the most pronounced activity in comparison to that of acetylsalycilic acid. A comparison of the published data on maximum drug concentrations in the blood plasma (Cmax) and the values of effective concentrations (EC25) of drugs determined in this study suggests that diabenol and glyclazide will produce direct antiaggregant effect under clinical administration conditions. At the same time, it is concluded that the antiaggregant effect of glibenclamide, glucophage and rosiglitazone is indirect and can only be pronounced at concentrations significantly exceeding the therapeutic level.